Pharmaceutical Executive August 4, 2025
Key Takeaways
- Computational chemistry and AI are integral to modern drug discovery, enhancing small molecule design and target selection with precision.
- Nimbus focuses on high unmet medical needs, selecting well-validated targets to create competitive advantages and best-in-class molecules.
- The company plans to advance its pipeline with novel therapies, including WRN and SIK inhibitors, aiming for significant clinical impact.
- Industry challenges include prioritizing speed over impactful targets, highlighting the need for outstanding scientists to leverage AI effectively.
Computational chemistry combined with AI technologies has become a powerful tool for assessing small molecule properties, high-resolution protein structures, and molecular mechanism of action, as well as optimizing target selection and small molecule design.
Dr. Peter Tummino, president of R&D at Nimbus,...
Today's Sponsors
Today's Sponsor